Zobrazeno 1 - 10
of 232
pro vyhledávání: '"Olivier Rixe"'
Autor:
Thomas F Gajewski, John A Thompson, Sanjay Goel, Brendan D Curti, Elisabeth I Heath, Olivier Rixe, David C Smith, Celine Jacquemont, Tycel Phillips, Martin Gutierrez, Sahar Ansari, Andrew L Coveler, Svetomir N Markovic, Timothy M Kuzel, Amitkumar N Mehta, David L Bajor, Hun Ju Lee, Ajay K Gopal, Paolo Caimi, Ariel Topletz-Erickson, Peigen Zhou, Michael W Schmitt, Juneko E Grilley-Olson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG1 antibody that activates CD40, an immune-activating tumor necrosis factor receptor superfamily member. SEA-CD40 exhibits enhanced binding to activating FcγRIIIa, po
Externí odkaz:
https://doaj.org/article/997d45d0420040f2a6abbe4400763c7d
Autor:
Ramses Sadek, Olivier Rixe, David Munn, Christopher M Smith, Yousef Zakharia, Joseph Drabick, Kenneth F Grossmann, Robert R McWilliams, Montaser F Shaheen, Ravindra Kolhe, Rafal Pacholczyk, Lucinda L Tennant, Eugene P Kennedy, Charles J Link Jr, Nicholas N Vahanian, Jiayi Yu, Steven S Shen, Erik L Brincks, Gabriela R Rossi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background The indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressiv
Externí odkaz:
https://doaj.org/article/3e3e02066379461ebd661d3bcc62f60a
Autor:
Yi Liu, Capucine Baldini, Jameel Muzaffar, David Hong, Olivier Rixe, Christophe Massard, Timothy Yap, Solmaz Sahebjam, Ursa Brown-Glaberman, Andreea Varga, Sergey Efuni, Barbara Kapelan, Eniola Ogunmefun, Tomonori Tayama, Henry Zhao, Denis Healy, Robert Latek, Daisuke Nakashima, Emrullah Yilmaz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/661ac478574745f894f0fe0eb1116527
For more than 30 years, Skeel's Handbook of Cancer Therapy (formerly Handbook of Cancer Chemotherapy) has been the resource of choice for current, reliable information on cancer treatment for most adults. The 9th Edition reflects recent significant a
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Supplementary Table from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06e8274a662db94b0372cb7e7542e809
https://doi.org/10.1158/1078-0432.22486856
https://doi.org/10.1158/1078-0432.22486856
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Purpose:TRX518 is a mAb engaging the glucocorticoid-induced TNF receptor−related protein (GITR). This open-label, phase I study (TRX518-003) evaluated the safety and efficacy of repeated dose TRX518 monotherapy and in combination with gemcitabine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d505d5d9e72ee2c945357f5aef741ec3
https://doi.org/10.1158/1078-0432.c.6532406.v1
https://doi.org/10.1158/1078-0432.c.6532406.v1
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Supplementary Data from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b804d37d72c5b64ee02158bbc8605da
https://doi.org/10.1158/1078-0432.22486880
https://doi.org/10.1158/1078-0432.22486880
Autor:
Jason J. Luke, Jedd D. Wolchok, Taha Merghoub, Cynthia A. Sirard, Diane Piper, Lianna Sifferlen, Phillip Wong, Aliya Holland, Jingjing Qi, Walter Newman, Olivier Rixe, David Bajor, Todd Bauer, Takami Sato, Girish S. Naik, Hong Wang, Roberta Zappasodi, Diwakar Davar
Supplementary Figure from Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3addefab290e824d920fb0999caa57c8
https://doi.org/10.1158/1078-0432.22486877
https://doi.org/10.1158/1078-0432.22486877
Autor:
Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd Bauer, David Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, Aliya Holland, Phillip Wong, Lianna Sifferlen, Diane Piper, Cynthia A. Sirard, Taha Merghoub, Jedd D. Wolchok, Jason J. Luke
Publikováno v:
Clin Cancer Res
Purpose: TRX518 is a mAb engaging the glucocorticoid-induced TNF receptor−related protein (GITR). This open-label, phase I study (TRX518-003) evaluated the safety and efficacy of repeated dose TRX518 monotherapy and in combination with gemcitabine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60473b0d4d51a50755b6880e00e30770
https://europepmc.org/articles/PMC9475244/
https://europepmc.org/articles/PMC9475244/
Autor:
Robert Wesolowski, Anne M. Noonan, Richard Charles Curry, John Charles Morris, Carolyn Muller, Vinay K. Puduvalli, Olivier Rixe, John L. Villano, Trisha Michel Wise-Draper, Emrullah Yilmaz, Gilles Tapolsky, Ray Takigiku
Publikováno v:
Journal of Clinical Oncology. 41:93-93
93 Background: Chemotherapy Induced Peripheral Neuropathy (CIPN) is a debilitating side effect associated with many chemotherapeutic agents. It significantly impacts quality of life during treatment, causes lasting neuropathy, and may also shorten th